Rare Diseases
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.
Showing 1–12 of 81 articles
Quick answer
NovaPharmaNews Rare Diseases hub for FDA covers 81 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
FDA · rare disease · 5 min
Dr. Sarah MitchellFDA Priority Review Voucher Program: Will Makary's Initiative Survive?
FDA · 7 min
Dr. Sarah MitchellBioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams
FDA · rare disease · 6 min
Dr. Sarah MitchellFDA Hold Puts Aardvark Prader-Willi Drug in Limbo: Implications for Pharma BD
FDA · Prader-Willi syndrome · 8 min
Dr. Sarah MitchellServier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal
muscular dystrophy · 13 min
Dr. Sarah MitchellImmunovant's IMVT-1402 Shows Blockbuster Potential in Autoimmune Disease; Wave Life Sciences Advances RNA Editing
FDA · autoimmune disease · 9 min
Dr. Sarah MitchellGlobal Regulatory Roundup: Key Updates for June 1, 2026
FDA · Dermatologicals · 7 min
Dr. Sarah MitchellPalvella Secures $230M to Advance QTORIN for Rare Diseases
rare disease · 2 min
Dr. Sarah MitchellPalvella's Pivotal Rare-Disease Data and Financial Outlook
rare disease · 4 min
Dr. Sarah MitchellPalvella's Nasdaq Uplisting: Implications for Rare Disease Development
rare disease · 3 min
Dr. Sarah MitchellPalvella's Pivotal Data and Cash Runway: Implications for Rare Diseases
rare disease · 5 min
Dr. Sarah MitchellFierce Biotech Week: Key Takeaways and Emerging Trends
biotech · 12 min
Dr. Laura BennettFrequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.
Explore intelligence